References of "RORIVE, Andrée"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCancer du sein : de la thérapie ciblée à la médecine personnalisée
JERUSALEM, Guy ULg; COLLIGNON, Joëlle ULg; Josse, Claire ULg et al

in Revue Médicale de Liège (2015), 70(5-6), 269-276

Dans cet article, les auteurs passent en revue les grands principes de prise en charge du traitement systémique du cancer du sein et posent la question suivante : jusqu'où réellement aujourd'hui ce ... [more ▼]

Dans cet article, les auteurs passent en revue les grands principes de prise en charge du traitement systémique du cancer du sein et posent la question suivante : jusqu'où réellement aujourd'hui ce traitement est-il individualisé ? Les nouvelles technologies permettent une analyse détaillée des anomalies génomiques au niveau des cellules cancéreuses. Malheureusement, nous n'avons pas encore compris comment utiliser au mieux ces données au bénéfice du patient. La majorité des modifications du génome sont des évènements relativement rares compliquant le développement de nouveaux médicaments dans le cadre d'une médecine de précision. De plus, les tumeurs présentent une grande hétérogénéité temporelle et spatiale dont il faudra tenir compte lors de ce développement. Une collaboration internationale intensive est en cours pour tenter de confirmer que la médecine de précision permet d'optimiser les résultats du traitement systémique dans le cancer du sein. [less ▲]

Detailed reference viewed: 77 (2 ULg)
Full Text
Peer Reviewed
See detailChemotherapy options for patients suffering from heavily pretreated metastatic breast cancer.
Jerusalem, Guy ULg; RORIVE, Andrée ULg; COLLIGNON, Joëlle ULg

in Future oncology (London, England) (2015), 11(12), 1775-89

ABSTRACT The identification of additional chemotherapy agents for anthracycline- and taxane-pretreated advanced breast cancer (ABC) is an urgent medical need. Single agent chemotherapy is most times ... [more ▼]

ABSTRACT The identification of additional chemotherapy agents for anthracycline- and taxane-pretreated advanced breast cancer (ABC) is an urgent medical need. Single agent chemotherapy is most times administered because combined therapy is only associated with modest, if any, improvement in median progression-free survival. Randomized trials failed to show overall survival benefit compared with single agent chemotherapy. We hope to modify the natural history of ABC by the consecutive use of treatments with documented activity in heavily pretreated patients. Quality of life remains an important end point as cure is in general not possible. We first review the activity of the approved and the most frequently used agents in heavily pretreated ABC. Thereafter, the potential role and safety profile of etirinotecan pegol is discussed given the results recently released of a Phase III trial comparing this agent to Treatment of Physician's Choice. [less ▲]

Detailed reference viewed: 17 (0 ULg)
Full Text
Peer Reviewed
See detailCancer du sein: intérêt du bilan d’extension par imagerie lors du diagnostic initial et du suivi les trois premières années après le diagnostic
SCHROEDER, Hélène ULg; Hanocq, Florence ULg; COLLIGNON, Joëlle ULg et al

in Revue Médicale de Liège (2015), 70(3), 140-147

In our region, repeated tumor staging by radiological procedures aiming to detect relapses and/or metastases from breast cancer is frequently performed. However, these procedures are not recommended by ... [more ▼]

In our region, repeated tumor staging by radiological procedures aiming to detect relapses and/or metastases from breast cancer is frequently performed. However, these procedures are not recommended by current international guidelines. We retrospectively analyzed the charts from 818 patients with a new diagnosis of breast cancer seen at CHU Liege between 2005 and 2009. We assessed the role of staging procedures at initial diagnosis and during follow-up the first 3 years after the diagnosis of breast cancer. Twenty-six patients presented with metastatic disease at diagnosis and 55 patients developed loco-regional relapses or metastases during follow-up. For asymptomatic patients, imaging procedures only detected tumor metastases or relapse without elevated tumor markers in 9 patients at initial diagnosis and 10 patients during follow-up. The diagnosis of an asymptomatic relapse and/or metastases had no positive impact on progression-free or overall survival. The anatomic extension identified patients at high risk for presenting distant metastases already at the time of initial diagnosis and the biological aggressiveness evaluated by Ki-67 was an important prognostic factor for early relapse. In view of these results, we do not recommend staging and searching for metastatic disease in asymptomatic patients presenting early stage breast cancer with low expression of the Ki-67 at the time of initial diagnosis. We also do not recommend repeated staging and searching for metastases by imaging in asymptomatic patients during routine follow-up. Staging should only be performed if a relapse is suspected during follow-up. [less ▲]

Detailed reference viewed: 33 (4 ULg)
Full Text
Peer Reviewed
See detailVISMODEGIB ET CARCINOMES BASOCELLULAIRES LOCALEMENT AVANCES
LEBAS, Eglantine ULg; RORIVE, Andrée ULg; EL HAYDERI, Lara ULg et al

in Revue Médicale de Liège (2015)

Basal cell carcinoma is the most frequent skin cancer. Even though metastases are exceptional, these cancers may be locally highly aggressive. The Hedgehog signaling pathway plays a significant role in ... [more ▼]

Basal cell carcinoma is the most frequent skin cancer. Even though metastases are exceptional, these cancers may be locally highly aggressive. The Hedgehog signaling pathway plays a significant role in the pathogenesis of basal cell carcinoma. Vismodegib is a selective inhibitor of this pathway and may be administered orally. Its main indication is locally advanced basal cell carcinoma, when other therapeutic options have failed or are contra-indicated. Vismodegib can also be used as prophylactic therapy in the Gorlin syndrome or basal cell nevomatosis. Its principal adverse effects are muscle spasms, alopecia and altered taste. They are frequent, but often moderate in intensity; they sometimes restrict continuation of treatment. Two clinical cases are presented, relating the efficacity and tolerance of this new therapeutic option. [less ▲]

Detailed reference viewed: 37 (3 ULg)
Full Text
Peer Reviewed
See detailRecurrent In Situ Melanoma Successfully Treated with Ingenol Mebubate
MANSUY, Marion ULg; TASSOUDJI, Nazli ULg; ARRESE ESTRADA, Jorge ULg et al

in Dermatologic Therapy (2014)

Background:Treatment options for melanoma in situ (MIS) include imiquimod, radiation therapy, cryotherapy, excisional and Mohs surgery. Ingenol mebutate is a new topical treatment option recognized for ... [more ▼]

Background:Treatment options for melanoma in situ (MIS) include imiquimod, radiation therapy, cryotherapy, excisional and Mohs surgery. Ingenol mebutate is a new topical treatment option recognized for actinic keratosis. Although in vitro effectiveness has been demonstrated on melanoma cell lines, its therapeutic potential for in vivo melanomas is unknown. Case Report: In 2011, a 91-year-old woman presented a thick melanoma of her cheek. The lateral sections revealed persisting in situ melanoma, which were again excised. She presented for follow-up and a recurrent MIS was evidenced centered on the previous scar. She refused further surgery and ingenol mebutate (0.015% gel) was administered on three consecutive days. One month later, a complete clinical resolution was observed. Histology and immunohistology revealed no residual MIS. Conclusion: In this patient, ingenol mebutate was successful and well-tolerated as a topical, alternative therapy for MIS after failure of other treatment options. [less ▲]

Detailed reference viewed: 24 (1 ULg)
Full Text
Peer Reviewed
See detailUse of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.
Jerusalem, Guy ULg; RORIVE, Andrée ULg; COLLIGNON, Joëlle ULg

in Breast Cancer (2014), 6

Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents ... [more ▼]

Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents. Recently, everolimus, a mammalian target of rapamycin (mTOR) inhibitor, combined with exemestane, an aromatase inhibitor, has been approved in Europe and the USA for patients suffering from estrogen receptor-positive, HER2-negative advanced breast cancer previously treated by a nonsteroidal aromatase inhibitor, based on the results of BOLERO-2 (Breast cancer trials of OraL EveROlimus). This study showed a statistically significant and clinically meaningful improvement in median progression-free survival. Results concerning the impact on overall survival are expected in the near future. This clinically oriented review focuses on the use of mTOR inhibitors in breast cancer. Results reported with first-generation mTOR inhibitors (ridaforolimus, temsirolimus, everolimus) are discussed. The current and potential role of mTOR inhibitors is reported according to breast cancer subtype (estrogen receptor-positive HER2-negative, triple-negative, and HER2-positive ER-positive/negative disease). Everolimus is currently being evaluated in the adjuvant setting in high-risk estrogen receptor-positive, HER2-negative early breast cancer. Continuing mTOR inhibition or alternatively administering other drugs targeting the phosphatidylinositol-3-kinase/protein kinase B-mTOR pathway after progression on treatments including an mTOR inhibitor is under evaluation. Potential biomarkers to select patients showing a more pronounced benefit are reviewed, but we are not currently using these biomarkers in routine practice. Subgroup analysis of BOLERO 2 has shown that the benefit is consistent in all subgroups and that it is impossible to select patients not benefiting from addition of everolimus to exemestane. Side effects and impact on quality of life are other important issues discussed in this review. Second-generation mTOR inhibitors and dual mTOR-phosphatidylinositol-3-kinase inhibitors are currently being evaluated in clinical trials. [less ▲]

Detailed reference viewed: 40 (5 ULg)
Full Text
See detailPaclitaxel-Related Lymphedema and Scleroderma-Like Skin Changes
COLSON, Fany ULg; SIGHA, Berline; ARRESE ESTRADA, Jorge ULg et al

in Journal of Clinical Case Reports (2013), 3(11),

Paclitaxel is an antimucrotubule agent used for the treatment of metastatic breast cancer. The development of scleroderma-like skin changes is an exceptional adverse effect. We report two patients with ... [more ▼]

Paclitaxel is an antimucrotubule agent used for the treatment of metastatic breast cancer. The development of scleroderma-like skin changes is an exceptional adverse effect. We report two patients with metastatic breast cancer treated by paclitaxel who presented an enexplained unilateral lymphedema of the upper limb. Medical work-up did not demonstrate any mechanical or tumor obstruction of the lymphatic vessels. Dermatologic examination revealed cutaneous and bucutaneous indurations and hardening of certain areas of the involved arm. The clinical suspicion of scleroderma was confirmed by histology and immunohistology. Treatment was initiated with methotrexate and methylprednisolone, resulting in a clear reduction of the lymphedema and a regression of the scleroderma. These two cases suggest a pathogenic role of paclitaxel-induced scleroderma in the subsequent development of severe localized lymphedema. [less ▲]

Detailed reference viewed: 67 (10 ULg)
Full Text
See detailLe vemurafenib, une avancée majeure dans le traitement du mélanome métastatique exprimant le BRAF V600E
EL HAYDERI, Lara ULg; RORIVE, Andrée ULg; NIKKELS, Arjen ULg

in Skin Inc (2012)

Malgré une sensibilisation de la population concernant les dangers du soleil, des techniques diagnostiques très sensibles comme la dermoscopie et une diminution constante de l'épaisseur des mélanomes lors ... [more ▼]

Malgré une sensibilisation de la population concernant les dangers du soleil, des techniques diagnostiques très sensibles comme la dermoscopie et une diminution constante de l'épaisseur des mélanomes lors du premier diagnostic, il existe toujours des cas où le diagnostic arrive trop tard. Le pronostic du mélanome métastatique (stade IV) reste alors péjoratif avec une survie n'excédant pas les 5% à 5 ans. Les traitements par agents chimiothérapeutiques comme le DTIC (dacarbazine), les immunothérapies comme l'interféron ou les vaccinations à base de cellules dendritiques ne donnent que très peu d'espoir dans cette indication. Heureusement, des avancées significatives sont rapportées dans le traitement du mélanome métastatique exprimant la mutation BRAF V600E avec un inhibiteur de la BRAF kinase, le vemurafinib. Les résultats d'une étude de phase III montrent une diminution de 63 % du risque de décès et de 74 % du risque de progression avec le vemurafenib, par rapport à la chimiothérapie par DTIC. Le vemurafenib est associé à de nombreux effets indésirables cutanés (rash, alopécie, kérato-acanthome, carcinomes spinocellulaires, photosensibilité ...), qu'il est important de reconnaître pour pouvoir assurer une prise en charge thérapeutique adéquate. [less ▲]

Detailed reference viewed: 35 (3 ULg)
Full Text
See detailVitamine D et mélanome
NIKKELS, Arjen ULg; RORIVE, Andrée ULg; CAVALIER, Etienne ULg

in Skin Inc (2012), 15(3), 35

Detailed reference viewed: 48 (24 ULg)
Full Text
Peer Reviewed
See detailHow to manage hair changes in cancer patients.
FRANCHIMONT, Claudine ULg; QUATRESOOZ, Pascale ULg; RORIVE, Andrée ULg et al

in Vereecken, P.; Awada, A. (Eds.) Handbook of skin care in cancer patients. (2012)

Detailed reference viewed: 23 (4 ULg)
Full Text
Peer Reviewed
See detailLe cancer du sein chez la femme jeune
ANDRE, Chantal ULg; COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 397-399

Detailed reference viewed: 108 (15 ULg)
Full Text
Peer Reviewed
See detailAccelerated partial breast irradiation: state of the art
COUCKE, Philippe ULg; JANSEN, Nicolas ULg; JANVARY, Zsolt Levente ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2011), 5(1), 3-7

Accelerated partial breast irradiation can be applied by means of different techniques. It <br />offers an opportunity for reducing the treatment duration considerably and harbours the <br />potential for ... [more ▼]

Accelerated partial breast irradiation can be applied by means of different techniques. It <br />offers an opportunity for reducing the treatment duration considerably and harbours the <br />potential for less exposure of healthy tissue to higher radiation doses. However, evidence <br />issued from randomized trials is limited. European and American experts call our attention <br />to the potential dangers of widespread implementation of these techniques without any <br />long-term data on outcome and ask for complete information of patients on the potential <br />hazards and risks if accelerated partial breast irradiation is used instead of whole breast <br />irradiation. [less ▲]

Detailed reference viewed: 59 (8 ULg)
Full Text
Peer Reviewed
See detail18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers
Withofs, Nadia ULg; Grayet, Benjamin ULg; Tancredi, Tino ULg et al

in Nuclear Medicine Communications (2011), 32(3), 168-176

Detailed reference viewed: 67 (28 ULg)
Full Text
Peer Reviewed
See detailPre-study and in-study validation of a SPE-LC-MS-MS method for the determination of 5-S-cysteinyldopa, a melanoma biomarker, in human plasma.
Martin, Gaelle; Mansion, François ULg; Houbart, Virginie ULg et al

in Talanta (2011), 84(2), 280-6

The incidence of malignant melanoma has increased over the past decades, particularly in Caucasian population. This disease presents defavourable prognosis in terms of survey, especially when detection ... [more ▼]

The incidence of malignant melanoma has increased over the past decades, particularly in Caucasian population. This disease presents defavourable prognosis in terms of survey, especially when detection occurs at the metastatic phase. Reliable analytical methods for biomarker determination are thus an interesting tool in pathology detection and follow-up. In this context, a method using SPE-LC-ESI-MS-MS for the determination of 5-S-cysteinyldopa (5-SCD) in human plasma was optimized. The presence of matrix effect was investigated in details while 5-SCD stability was studied according to FDA requirements for the validation of bioanalytical methods. Pre-study and in-study validations of the entire method were then successfully performed by applying the approach based on total measurement error and accuracy profiles over a concentration ranges from 1.6 to 200 ng/ml. Good results with respect to accuracy, trueness and precision were obtained. The maximum risk of observing future measurements falling outside the acceptance limits during routine analysis was also estimated. [less ▲]

Detailed reference viewed: 56 (8 ULg)
Full Text
Peer Reviewed
See detailLe cancer du sein de la femme âgée
MARTIN, Marie; COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 400-408

Detailed reference viewed: 52 (5 ULg)
Full Text
Peer Reviewed
See detailCancer du sein et métastases cérébrales
RORIVE, Andrée ULg; COLLIGNON, Joëlle ULg; MARTIN, Marie et al

in Revue Médicale de Liège (2011), 66(5-6), 299-305

Detailed reference viewed: 87 (4 ULg)